🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
9.38
-0.22 (-2.29%)
At close: Nov 18, 2026, 4:00 PM EST
9.24
-0.14 (-1.49%)
Pre-market: Nov 19, 2026, 4:01 AM EST

Bicara Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
54.3230.5118.779.276.34
Research & Development
182.7125.163.6230.6231.31
Operating Expenses
237.03155.682.3939.8937.66
Operating Income
-237.03-155.6-82.39-39.89-37.66
Interest Expense
-----0.11
Interest & Investment Income
16.9617.8714.581.310
Other Non Operating Income (Expenses)
----13.41-0.08
Pretax Income
-220.06-137.73-67.81-51.98-37.84
Income Tax Expense
0.220.220.190.010
Net Income
-220.28-137.95-68-51.99-37.85
Net Income to Common
-220.28-137.95-68-51.99-37.85
Net Income Growth
-----
Shares Outstanding (Basic)
63551710
Shares Outstanding (Diluted)
63551710
Shares Change
15.60%225.35%2796.96%35.20%-
EPS (Basic)
-3.49-2.52-4.05-89.61-88.20
EPS (Diluted)
-3.49-2.52-4.05-89.61-88.20
EPS Growth
-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-162.75-107.11-74.82-46.21-32.27
Free Cash Flow Per Share
-2.58-1.96-4.45-79.66-75.20
EBITDA
-236.83-155.5-82.33-39.87-37.65
D&A For EBITDA
0.190.110.060.020.01
EBIT
-237.03-155.6-82.39-39.89-37.66
SEC Filings: 10-K · 10-Q